182例初诊多发性骨髓瘤伴高危细胞遗传学异常患者的预后分析
该回顾性研究纳入182例初诊多发性骨髓瘤患者,用FISH检测高危细胞遗传学异常(HRCA)及不同异常组合。结果发现1种HRCA伴非HRCA组与双/三打击组生存相似且均劣于单一HRCA组,提示基于FISH检测双/三打击具有预后价值。
要点
- 1种HRCA伴非HRCA与双/三打击组生存相似,均劣于单一HRCA组。
- 1种HRCA伴其他遗传学异常组中位PFS 15.1个月,短于单一HRCA组32.2个月。
- 基于FISH细胞遗传学检测双/三打击对初诊MM具有预后意义。
核心结论
- 基于FISH细胞遗传学检测双/三打击对初诊多发性骨髓瘤具有重要预后价值。
研究设计与样本
- 回顾性研究纳入2009年11月至2018年5月吉林大学第一医院182例初诊多发性骨髓瘤患者。
- HRCA包括FISH检出的1q+、del(17p)、t(4;14)、t(14;16),非HRCA包括del(13q)、t(11;14)。
- 比较单一HRCA组、1种HRCA伴非HRCA组及≥2种HRCA(双/三打击)组的临床特征与生存。
主要发现
- 1种HRCA伴非HRCA组与双/三打击组中位PFS分别为19.1和12.1个月(P=0.248),中位OS分别为29.6和29.3个月(P=0.774)。
- 上述两组中位PFS均低于单一HRCA组的32.2个月(P=0.040,P=0.001),中位OS均低于单一HRCA组的42.3个月(P=0.021,P=0.041)。
- 1种HRCA伴其他遗传学异常组中位PFS 15.1对32.2个月(HR=2.126,95%CI 1.176~3.843,P=0.005)。
- 1种HRCA伴其他遗传学异常组中位OS 29.3对42.3个月(HR=1.442,95%CI 0.705~2.950,P=0.011)。
关键数值与推荐
- HRCA定义为FISH检出1q+、del(17p)、t(4;14)、t(14;16)。
- 非HRCA定义为FISH检出del(13q)、t(11;14)。
- 双/三打击定义为≥2种HRCA。
临床怎么用
- 对初诊多发性骨髓瘤患者应行FISH细胞遗传学检测以识别HRCA及双/三打击。
- 伴1种HRCA合并其他遗传学异常者预后接近双/三打击,需加强风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: To evaluate the clinical characteristics and prognosis of high risk cytogenetic abnormalities (HRCA) and various combinations of cytogenetic abnormality in patients with newly-diagnosed multiple myeloma (NDMM) . Methods: This retrospective study collected 182 NDMM patients in the First Affiliated Hospital of Jilin University between Nov. 2009 and May 2018. HRCA included 1q+, del (17p) , t (4;14) , and t (14;16) detected by FISH, and non-HRCA included del (13q) , t (11;14) detected by FISH. The clinical characteristics among three groups, including cases who carrying a single HRCA, 1 HRCA in combination with non-HRCA and cases carrying two or more HRCAs (double/triple-hit) were observed. Kaplan-Meier curve was used to analyze both progression-free survival (PFS) and overall survival (OS) for the three groups. Results: The survivals of patients with 1 HRCA in combination with non-HRCA were similar to those with two or more HRCAs (double/triple-hit) , the median PFS (mPFS) was 19.1 m vs 12.1 m (P=0.248) and median OS (mOS) was 29.6 m vs 29.3 m (P=0.774) . Furthermore, the prognosis of these two groups were both inferior to patients with a single HRCA, respectively. (mPFS: 32.2 m, P=0.040, P=0.001; mOS: 42.3 m, P=0.021, P=0.041) . Strikingly, both the mPFS and the mOS of patients with 1 HRCA in combination with non-HRCA (regardless of high risk or not) were significantly shorter than that of cases with a single HRCA (mPFS: 15.1 m vs 32.2 m, HR=2.126, 95%CI 1.176-3.843, P=0.005; mOS: 29.3 m vs 42.3 m, HR=1.442, 95%CI 0.705-2.950, P=0.011) . Conclusion: It is of prognostic significance value for detecting double/triple-hit based on FISH cytogenetics in NDMM. 目的: 分析伴高危细胞遗传学异常(HRCA)及不同遗传学异常组合的初治多发性骨髓瘤(MM)患者的临床特征及预后,探讨HRCA的预后价值。 方法: 回顾性分析2009年11月至2018年5月收治的182例初诊MM患者。HRCA包括FISH检出的1q+、del(17p)、t(4;14)、t(14;16),非HRCA包括FISH检出的del(13q)、t(11;14)。比较仅携带单一HRCA与1种HRCA伴非HRCA及≥2种HRCA(即"双/三打击")组间临床特征的差异,应用Kaplan-Meier曲线分析其对生存的影响。 结果: 1种HRCA伴非HRCA组与≥2种HRCA组(即"双/三打击")中位无进展生存(PFS)时间分别为19.1和12.1个月(P=0.248),中位总生存(OS)时间为29.6和29.3个月(P=0.774),均分别低于仅携带单一HRCA组(中位PFS时间32.2个月,P=0.040,P=0.001;中位OS时间42.3个月,P=0.021,P=0.041)。合并分析后显示:1种HRCA伴其他遗传学异常组(无论高危、非高危)生存时间较仅携带单一HRCA组明显缩短[中位PFS时间15.1对32.2个月(HR=2.126,95%CI 1.176~3.843,P=0.005);中位OS 29.3对42.3个月(HR=1.442,95%CI 0.705~2.950,P=0.011)]。 结论: 基于FISH细胞遗传学检测"双/三打击"具有重要预后价值。.
引用
- Liu XL, Bai J, Fan HQ, et al. [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31495130. doi:10.3760/cma.j.issn.0253-2727.2019.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。